

REMARKS


The specification has been amended to provide a cross-reference to the previously filed International Application. The claims have also been amended to delete improper multiple dependencies and to place the application into better form for examination. Entry of the present amendment and favorable action on the above-identified application are earnestly solicited.

Attached hereto is a marked-up copy of the changes made to the application by this Amendment.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By  #32865
Raymond C. Stewart, #21,066

RCS/cgc
3813-0101P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Attachment: Version With Markings Showing Changes Made

(Rev. 01/22/01)

VERSION WITH MARKINGS SHOWING CHANGES MADE

The specification has been amended to provide cross-referencing to the International Application.

The claims have been amended as follows:

5. (Amended) A composition for use in immune therapy, comprising lymphocytes obtained by amplifying mainly NK cells or non-MHC-bound or MHC-bound killer T cells by incubating lymphocytes and cells with a particular gene expressed in a particular cancer cell or cells in which said particular gene has already been expressed, and amplifying killer T cells specific to a cancer antigen by means of the method for the *in vitro* culture of the lymphocytes as claimed in [any one of claims 1 to 4]claim 1.

8. (Amended) The composition for use in immune therapy as claimed in [any one of claims 5 to 7]claim 5, wherein said lymphocytes are those collected immediately after separation from peripheral blood or those activated by an immunomodulator that can become likely to damage a cancer cell.